SI3219726T1 - Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti - Google Patents

Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti

Info

Publication number: SI3219726T1
Authority: SI; Slovenia
Prior art keywords: antibodies; functional fragments; tnf alpha; tnf; alpha
Prior art date: 2016-03-17

Application number

SI201631040T

Other languages

English (en)

Inventor

Tea Gunde

Sebastian Meyer

Esther Maria Furrer

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2016-03-17

Publication date

2021-02-26

2016-03-17 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2021-02-26 Publication of SI3219726T1 publication Critical patent/SI3219726T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Immunology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

SI201631040T 2016-03-17 2016-03-17 Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti SI3219726T1 (sl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
SI3219726T1 true SI3219726T1 (sl)	2021-02-26

Family

ID=55542576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI201631040T SI3219726T1 (sl)	2016-03-17	2016-03-17	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
SI201731446T SI3430043T1 (sl)	2016-03-17	2017-03-16	Anti-TNFalfa protitelesa in njihovi funkcionalni fragmenti

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI201731446T SI3430043T1 (sl)	2016-03-17	2017-03-16	Anti-TNFalfa protitelesa in njihovi funkcionalni fragmenti

Country Status (41)

Country	Link
US (3)	US11459383B2 (sl)
EP (3)	EP3219726B1 (sl)
JP (2)	JP7129398B2 (sl)
KR (2)	KR20220158877A (sl)
CN (1)	CN109071650B (sl)
AR (1)	AR107917A1 (sl)
AU (2)	AU2017235387B2 (sl)
BR (1)	BR112018016667A2 (sl)
CA (1)	CA3011784C (sl)
CL (1)	CL2018002649A1 (sl)
CO (1)	CO2018009783A2 (sl)
CR (1)	CR20180448A (sl)
CY (1)	CY1123784T1 (sl)
DK (2)	DK3219726T3 (sl)
EA (1)	EA039760B1 (sl)
ES (2)	ES2836349T3 (sl)
FI (1)	FI3430043T3 (sl)
GE (1)	GEP20217307B (sl)
HR (2)	HRP20231464T1 (sl)
HU (2)	HUE052773T2 (sl)
IL (1)	IL261031A (sl)
JO (2)	JOP20170064B1 (sl)
LT (2)	LT3219726T (sl)
MA (1)	MA43717B1 (sl)
MD (1)	MD3430043T2 (sl)
MX (1)	MX2018011258A (sl)
MY (1)	MY194041A (sl)
PH (1)	PH12018501907A1 (sl)
PL (2)	PL3219726T3 (sl)
PT (2)	PT3219726T (sl)
RS (2)	RS61374B1 (sl)
SA (1)	SA518400027B1 (sl)
SG (1)	SG11201807062RA (sl)
SI (2)	SI3219726T1 (sl)
SM (2)	SMT202000706T1 (sl)
TN (1)	TN2018000298A1 (sl)
TW (2)	TWI829444B (sl)
UA (1)	UA128715C2 (sl)
UY (1)	UY37157A (sl)
WO (1)	WO2017158092A1 (sl)
ZA (5)	ZA201805919B (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты
SI3219726T1 (sl) *	2016-03-17	2021-02-26	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
PT3219727T (pt)	2016-03-17	2021-01-21	Tillotts Pharma Ag	Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
EP3456736B1 (en) *	2017-09-19	2021-04-07	Tillotts Pharma Ag	Antibody variants
ES2991804T3 (es) *	2017-09-19	2024-12-04	Tillotts Pharma Ag	Variantes de anticuerpos
EP3456737B1 (en) *	2017-09-19	2024-02-14	Tillotts Pharma Ag	Antibody variants
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
ATE356869T1 (de)	1990-01-12	2007-04-15	Amgen Fremont Inc	Bildung von xenogenen antikörpern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
MX9204374A (es)	1991-07-25	1993-03-01	Idec Pharma Corp	Anticuerpo recombinante y metodo para su produccion.
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt)	1991-12-02	2008-12-22	Medical Res Council	Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP1978033A3 (en)	1995-04-27	2008-12-24	Amgen Fremont Inc.	Human antibodies derived from immunized xenomice
CA2219486A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
BRPI9707379C8 (pt) *	1996-02-09	2017-12-12	Abbott Biotech Ltd	composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
ATE200679T1 (de)	1997-04-14	2001-05-15	Micromet Ag	Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
WO2000029584A1 (en)	1998-11-18	2000-05-25	Genentech, Inc.	Antibody variants with higher binding affinity compared to parent antibodies
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
DK2390267T3 (da)	2005-06-07	2013-08-26	Esbatech A Novartis Co Llc	Stabile og opløselige antistoffer, der hæmmer TNF(alfa)
WO2009155723A2 (en)	2008-06-25	2009-12-30	Esbatech, An Alcon Biomedical Research Unit Llc	STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
KR101834797B1 (ko)	2008-06-25	2018-03-07	에스바테크 - 어 노바티스 컴파니 엘엘씨	보편적 항체 프레임워크를 사용한 래빗 항체의 인간화
RU2522245C2 (ru)	2008-07-10	2014-07-10	ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи	Способы и композиции для улучшенной доставки макромолекул
BR112012025568A2 (pt)	2010-04-07	2017-03-28	Abbvie Inc	proteínas de ligação ao tnf-<244>.
EP2593476A2 (en)	2010-07-16	2013-05-22	Ablynx N.V.	Modified single domain antigen binding molecules and uses thereof
WO2012041018A1 (zh) *	2010-09-30	2012-04-05	成都康弘生物科技有限公司	抗TNFα的人源化抗体及其抗原结合片段Fab和用途
SG11201509899PA (en)	2013-06-26	2016-01-28	Numab Ag	Novel antibody frameworks
US9416197B2 (en) *	2013-11-01	2016-08-16	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune disease
KR20160142849A (ko) *	2014-03-26	2016-12-13	셀 메디카 스위처란트 아게	Tnf 알파에 대한 결합 구성원
EA039201B1 (ru)	2016-03-17	2021-12-16	Нумаб Инновейшн Аг	Антитела к фно и их функциональные фрагменты
US10787508B2 (en)	2016-03-17	2020-09-29	Numab Innovation Ag	Anti-TNFα-antibodies and functional fragments thereof
SI3219726T1 (sl) *	2016-03-17	2021-02-26	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
PT3219727T (pt)	2016-03-17	2021-01-21	Tillotts Pharma Ag	Anticorpos anti-tnf alfa e fragmentos funcionais dos mesmos
EP3456736B1 (en) *	2017-09-19	2021-04-07	Tillotts Pharma Ag	Antibody variants

2016
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 SM SM20200706T patent/SMT202000706T1/it unknown
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
2017
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 UA UAA201809317A patent/UA128715C2/uk unknown
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Ceased
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 DK DK17710748.9T patent/DK3430043T5/da active
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en active Application Filing
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 SM SM20230429T patent/SMT202300429T1/it unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/en active Pending
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active Active
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 AU AU2017235387A patent/AU2017235387B2/en active Active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-04 ZA ZA2018/05919A patent/ZA201805919B/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US12043663B2/en active Active
- 2022-10-03 US US17/958,759 patent/US12209122B2/en active Active
2024
- 2024-09-18 AU AU2024219840A patent/AU2024219840A1/en active Pending

Also Published As

Publication number	Publication date
US12043663B2 (en)	2024-07-23
DK3219726T3 (da)	2020-12-07
JOP20170064B1 (ar)	2021-08-17
EP3219726A1 (en)	2017-09-20
US20210198353A1 (en)	2021-07-01
ZA201805919B (en)	2024-12-18
EP4275745A3 (en)	2023-12-20
PL3219726T3 (pl)	2021-07-19
HUE064238T2 (hu)	2024-02-28
KR102470235B1 (ko)	2022-11-24
PT3219726T (pt)	2020-12-15
ZA202108600B (en)	2022-03-30
TWI829444B (zh)	2024-01-11
CO2018009783A2 (es)	2018-09-28
LT3430043T (lt)	2023-12-27
CY1123784T1 (el)	2022-05-27
PT3430043T (pt)	2023-11-23
TW201739766A (zh)	2017-11-16
AU2017235387B2 (en)	2024-06-27
CN109071650B (zh)	2022-05-13
IL261031A (en)	2018-10-31
PL3430043T3 (pl)	2024-03-11
SA518400027B1 (ar)	2022-03-06
TW202311288A (zh)	2023-03-16
SG11201807062RA (en)	2018-09-27
CL2018002649A1 (es)	2018-11-09
MA43717A (fr)	2018-11-28
MX2018011258A (es)	2019-02-13
HRP20210123T1 (hr)	2021-03-05
RS64830B1 (sr)	2023-12-29
DK3430043T5 (da)	2024-09-23
AU2024219840A1 (en)	2024-10-10
RS61374B1 (sr)	2021-02-26
DK3430043T3 (da)	2023-11-27
LT3219726T (lt)	2021-01-25
NZ745999A (en)	2024-08-30
HUE052773T2 (hu)	2021-05-28
FI3430043T3 (fi)	2023-11-17
UA128715C2 (uk)	2024-10-09
TWI784945B (zh)	2022-12-01
EA201891788A1 (ru)	2019-01-31
SI3430043T1 (sl)	2024-01-31
CA3011784C (en)	2024-04-23
JP2022130407A (ja)	2022-09-06
US12209122B2 (en)	2025-01-28
US20230279091A1 (en)	2023-09-07
KR20180120149A (ko)	2018-11-05
MD3430043T2 (ro)	2024-02-29
EP3430043B1 (en)	2023-08-30
SMT202000706T1 (it)	2021-01-05
JP7129398B2 (ja)	2022-09-01
CR20180448A (es)	2019-01-25
ES2836349T3 (es)	2021-06-24
AU2017235387A1 (en)	2018-09-27
JOP20210085A1 (ar)	2023-01-30
ZA202108601B (en)	2022-03-30
MA43717B1 (fr)	2023-11-30
ZA202108599B (en)	2022-03-30
TN2018000298A1 (en)	2020-01-16
JP2019512268A (ja)	2019-05-16
EP4275745A2 (en)	2023-11-15
KR20220158877A (ko)	2022-12-01
US11459383B2 (en)	2022-10-04
ZA202108602B (en)	2022-03-30
GEP20217307B (en)	2021-10-25
EP3219726B1 (en)	2020-12-02
EP3430043A1 (en)	2019-01-23
CN109071650A (zh)	2018-12-21
ES2963221T3 (es)	2024-03-26
BR112018016667A2 (pt)	2019-02-05
UY37157A (es)	2017-10-31
SMT202300429T1 (it)	2024-01-10
US20230272059A1 (en)	2023-08-31
EA039760B1 (ru)	2022-03-10
HRP20231464T1 (hr)	2024-03-01
MY194041A (en)	2022-11-09
AR107917A1 (es)	2018-06-28
CA3011784A1 (en)	2017-09-21
WO2017158092A1 (en)	2017-09-21
PH12018501907A1 (en)	2019-06-17

Publication	Publication Date	Title
IL283321A (en)	2021-07-29	Antibodies against muc16 and their uses
HK1254861A1 (zh)	2019-07-26	抗lag3抗體及其用途
HK1250238A1 (zh)	2018-12-07	抗angptl8抗體及其用途
HK1256381A1 (zh)	2019-09-20	抗pacap抗體及其用途
IL261140A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
ZA202108600B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
PL3292154T3 (pl)	2022-04-19	Przeciwciała przeciwko ludzkiemu HER3 i ich zastosowania
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
HK1254240A1 (zh)	2019-07-12	抗羥腐胺賴氨酸抗體及其用途
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
AU2017235061A1 (en)	2017-09-21	Anti-TNFalpha-antibodies and functional fragments thereof